Zurcher Kantonalbank Zurich Cantonalbank Grows Position in Alphatec Holdings, Inc. (NASDAQ:ATEC)

Zurcher Kantonalbank Zurich Cantonalbank raised its position in Alphatec Holdings, Inc. (NASDAQ:ATEC) by 94.5% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 23,579 shares of the medical technology company’s stock after buying an additional 11,459 shares during the quarter. Zurcher Kantonalbank Zurich Cantonalbank’s holdings in Alphatec were worth $356,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds have also modified their holdings of the business. Valeo Financial Advisors LLC lifted its position in Alphatec by 5.0% in the fourth quarter. Valeo Financial Advisors LLC now owns 19,025 shares of the medical technology company’s stock valued at $287,000 after purchasing an additional 900 shares during the period. RiverPark Advisors LLC boosted its stake in shares of Alphatec by 22.6% in the fourth quarter. RiverPark Advisors LLC now owns 5,033 shares of the medical technology company’s stock valued at $76,000 after buying an additional 928 shares in the last quarter. State Board of Administration of Florida Retirement System grew its holdings in Alphatec by 4.7% during the third quarter. State Board of Administration of Florida Retirement System now owns 22,904 shares of the medical technology company’s stock worth $297,000 after acquiring an additional 1,030 shares during the period. Spouting Rock Asset Management LLC raised its position in Alphatec by 8.8% in the third quarter. Spouting Rock Asset Management LLC now owns 13,592 shares of the medical technology company’s stock worth $176,000 after acquiring an additional 1,094 shares in the last quarter. Finally, BluePath Capital Management LLC acquired a new stake in Alphatec in the third quarter valued at $29,000. 66.35% of the stock is currently owned by hedge funds and other institutional investors.

Alphatec Trading Up 3.3 %

Alphatec stock opened at $13.65 on Friday. The stock has a 50-day moving average price of $13.39 and a 200 day moving average price of $13.53. Alphatec Holdings, Inc. has a 52 week low of $8.66 and a 52 week high of $19.14. The stock has a market cap of $1.91 billion, a PE ratio of -8.81 and a beta of 1.48. The company has a current ratio of 2.86, a quick ratio of 1.99 and a debt-to-equity ratio of 6.54.

Alphatec (NASDAQ:ATEC) last issued its quarterly earnings results on Tuesday, February 27th. The medical technology company reported ($0.37) EPS for the quarter, missing analysts’ consensus estimates of ($0.28) by ($0.09). The firm had revenue of $138.00 million for the quarter, compared to analyst estimates of $131.90 million. During the same period in the previous year, the business posted ($0.33) EPS. Alphatec’s quarterly revenue was up 30.3% on a year-over-year basis. Equities research analysts predict that Alphatec Holdings, Inc. will post -1.1 earnings per share for the current fiscal year.

Analysts Set New Price Targets

ATEC has been the subject of a number of research analyst reports. Wells Fargo & Company started coverage on shares of Alphatec in a report on Friday, February 9th. They issued an “overweight” rating and a $26.00 price target for the company. Canaccord Genuity Group reaffirmed a “buy” rating and issued a $25.00 price objective on shares of Alphatec in a research note on Wednesday, March 20th. Needham & Company LLC boosted their target price on Alphatec from $22.00 to $23.00 and gave the stock a “buy” rating in a research report on Thursday, March 28th. Finally, HC Wainwright restated a “buy” rating and issued a $20.00 price target on shares of Alphatec in a research report on Monday, March 4th. One equities research analyst has rated the stock with a sell rating and seven have given a buy rating to the company. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $23.63.

Insider Transactions at Alphatec

In related news, CFO John Todd Koning sold 121,601 shares of the company’s stock in a transaction on Friday, March 1st. The stock was sold at an average price of $13.30, for a total value of $1,617,293.30. Following the completion of the transaction, the chief financial officer now directly owns 430,856 shares in the company, valued at $5,730,384.80. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. In other news, CFO John Todd Koning sold 121,601 shares of the company’s stock in a transaction dated Friday, March 1st. The shares were sold at an average price of $13.30, for a total transaction of $1,617,293.30. Following the completion of the transaction, the chief financial officer now owns 430,856 shares of the company’s stock, valued at approximately $5,730,384.80. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, EVP Craig E. Hunsaker sold 41,560 shares of the stock in a transaction dated Monday, February 26th. The stock was sold at an average price of $15.05, for a total transaction of $625,478.00. Following the transaction, the executive vice president now owns 1,188,444 shares in the company, valued at $17,886,082.20. The disclosure for this sale can be found here. Insiders have sold 285,069 shares of company stock worth $3,971,495 over the last quarter. 29.12% of the stock is currently owned by insiders.

Alphatec Company Profile

Alphatec Holdings, Inc, a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally. It manufactures and sells implants and instruments through third-party suppliers. The company offers Alpha InformatiX product platform, including EOS imaging system that provides full-body imaging; VEA alignment mobile application, which leverages EOS technology to more quickly quantify alignment parameters on a mobile device; SafeOp Neural InformatiX System that automates electromyographic and somatosensory evoked potential monitoring; and Valence, an intra-operative system that integrates navigation and robotics into spine procedures, as well as Sigma Prone TransPsoas (PTP) Access and PTP Patient Positioning Systems.